Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.

ABSTRACT:

Aim

To molecularly characterize the tumor microenvironment and evaluate immunologic parameters in canine glioma patients before and after treatment with oncolytic human IL-12-expressing herpes simplex virus (M032) and in treatment naïve canine gliomas.

Methods

We assessed pet dogs with sporadically occurring gliomas enrolled in Stage 1 of a veterinary clinical trial that was designed to establish the safety of intratumoral oncoviral therapy with M032, a genetically modified oncolytic herpes simplex virus. Specimens from dogs in the trial and dogs not enrolled in the trial were evaluated with immunohistochemistry, NanoString, Luminex cytokine profiling, and multi-parameter flow cytometry.

Results

Treatment-naive canine glioma microenvironment had enrichment of Iba1 pos

SUBMITTER: Chambers MR 

PROVIDER: S-EPMC8955901 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature